Veracyte (VCYT) news
Recent news
Veracyte Q2 EPS USD 0.31
AInvest Wire · Jul 30, 2026Veracyte outlook 2026 - continues to expect adjusted EBITDA margin to be greater than 26%
Veracyte, Inc. (Nasdaq: VCYT) has reaffirmed its 2026 financial outlook, with expectations that its adjusted EBITDA margin will exceed 26% for the year. This update follows the company’s strong first-quarter performance, which saw total revenue grow by 21% year-over-year to $139.1 million and…
AInvest Wire · Jul 30, 2026Veracyte: outlook 2026 raises testing revenue guidance to $576 million to $582 million
AInvest Wire · Jul 30, 2026Veracyte outlook FY revenue growth 14-15%
Veracyte, Inc. (NASDAQ: VCYT) has provided an updated revenue outlook for fiscal year 2026, projecting growth in the range of 14-15% year-over-year. This guidance reflects the company’s continued focus on expanding its genomic testing services and strengthening its market position in oncology…
AInvest Wire · Jul 30, 2026Veracyte sees FY revenue $590M to $596M, saw $582M to $592M
AInvest Wire · Jul 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.